Also known as: Akos024437838 Molecular Formula C 11 H 21 NO 9 Molecular Weight 311.29 g/mol InChI Key RZALONVQKUWRRY-XOJLQXRJSA-N 1 2D Structure 2 Identification 2.1 Computed Descriptors 2.1.1 IUPAC Name (2R,3R)-2,3-dihydroxybutanedioic acid;(3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate 2.1.2 InChI InChI=1S/C7H15NO3.C4H6O6/c1-8(2,3)5-6(9)4-7(10)11;5-1(3(7)8)2(6)4(9)10/h6,9H,4-5H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t6-;1-,2-/m11/s1 2.1.3 InChI Key RZALONVQKUWRRY-XOJLQXRJSA-N 2.1.4 Canonical SMILES C[N+](C)(C)CC(CC(=O)[O-])O.C(C(C(=O)O)O)(C(=O)O)O 2.1.5 Isomeric SMILES C[N+](C)(C)C[C@@H](CC(=O)[O-])O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O 2.2 Synonyms 2.2.1 Depositor-Supplied Synonyms 2.3 Create Date 3 Chemical and Physical Properties
Inefficient intracellular methylations may lead to the chronic damage of numerous proteins, which might in turn be involved in atherothrombogenesis
The competition between Eli Lilly and Novo Nordisk dominates headlines, but behind them a wave of challengers, from Amgen to upstart biotechs, are probing new mechanisms and formulations
The goal of GLP-1 medications is to help you build a healthier relationship with food and support sustainable weight loss
In this regard, carnitine treatment resulted in a down-regulation of nitrotyrosine, NOX2, IL-1b, IL-6, TGF-b1, collagen type I and tissue inhibitor of metalloproteinase-1, together with an upregulation of IL-10 and matrix metalloproteinase-9 [13]
